Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Javier Munoz MD, MBA

Javier L. Munoz MD, MBA

Director, Lymphoma Program, Hematologist /Oncologist, Mayo Clinic, Phoenix, Arizona

Dr. Munoz specializes in treating lymphomas and he is the Director of the Lymphoma Program at Mayo Clinic in Arizona. He is certified in Hematology and Medical Oncology. Dr. Munoz studied medicine in the “Universidad Peruana Cayetano Heredia” in Lima, Peru. Subsequently, he completed his residency and fellowship in Hematology-Oncology at Henry Ford Hospital in Michigan. Dr. Munoz also completed a Master of Science in patient-based research and an Investigational Cancer Therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before relocating to Arizona. Dr. Munoz also obtained an executive MBA in healthcare leadership and management for physicians from the University of Texas.

He has been principal investigator in multiple cutting-edge lymphoma trials including immunotherapy and CAR T-cells. Within Mayo Clinic, Dr. Munoz is the Chair of the Feasibility Committee at a 3-site enterprise level and the Director of the Cancer Center Clinical Trials Office in Arizona. Dr. Munoz has published in internationally renowned journals including the New England Journal of Medicine, Nature Reviews, Blood, and JAMA. Dr. Munoz's personal goal is the development of non-chemotherapy agents, via novel clinical trials, to serve patients suffering with cancer.

Disclosures

Consulting – Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly; Research funding – Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene. Honoraria - Targeted Oncology, OncView, Curio, Physicians' Education Resource, and Seattle Genetics.